Volume discount To see volume pricing visit each product page and scroll to the bottom of the page where you can see volume discounts based on quantity. Discount is automatically calculated once you add certain quantity of product to the cart.
Description Active substance: IGF-1 LR3 (Insulin-like growth factor 1) Purity/standard: 99% Packaging: sterile vial 1 mg Shipped from: EU
This
product is intended for laboratory research use only. It is not for use
as food additives, drugs, cosmetic, household chemicals or other
inappropriate applications. The customer acknowledges that the product
will be handled only by qualified and trained professionals.
Insulin-like
growth factor 1 (IGF-1) is a polypeptide protein hormone similar in
molecular structure to insulin. It plays an important role in childhood
growth and continues to have anabolic effects in adults.
Its
primary action is mediated by binding to specific IGF receptors present
on many cell types in many tissues. The signal is transduced by
intracellular events. IGF-1 is one of the most potent natural
activators of the AKT signaling pathway, a stimulator of cell growth
and multiplication and a potent inhibitor of programmed cell death.
Almost
every cell in the human body is affected by IGF-1, especially cells in
muscle, cartilage, bone, liver, kidney, nerves, skin, and lungs. In
addition to the insulin-like effects, IGF-1 can also regulate cell
growth and development, especially in nerve cells, as well as cellular
DNA synthesis.
IGF-1 has been manufactured recombinantly on a
large scale using both yeast and E. coli. Several companies have
evaluated IGF-1 in clinical trials for a variety of indications,
including growth failure, type 1 diabetes, type 2 diabetes, amyotrophic
lateral sclerosis (ALS aka "Lou Gehrig's Disease"), severe burn injury
and myotonic muscular dystrophy (MMD). Results of clinical trials
evaluating the efficacy of IGF-1 in type 1 diabetes and type 2 diabetes
showed great promise in reducing hemoglobin A1C levels, as well as
daily insulin consumption. However, the sponsor, Genentech,
discontinued the program due to an exacerbation of diabetic retinopathy
in patients coupled with a shift in corporate focus towards oncology.
Cephalon and Chiron conducted two pivotal clinical studies of IGF-1 for
ALS, and although one study demonstrated efficacy, the second was
equivocal, and the product has never been approved by the FDA.
